Therapy / Class: Antacid / Proton Pump Inhibitor (PPI)
Mechanism of Action:
It inhibits the gastric H+, K+-ATPase (the proton pump) which catalyzes the exchange of Hydrogen & Potassium Ion which in turn is responsible for Acid Formulation. It is effective in the inhibition of both basal acid secretion & stimulated acid secretion.
Indications:
Short-Term Treatment of
1 to 11 years of age:
- Symptomatic Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis (EE)
12 to 17 years of age:
- Non-erosive GERD
- Erosive Esophagitis (EE)
- Maintenance of Healing of EE
- Pathological Hyper-secretory Conditions Including Zollinger-Ellison Syndrome(ZES)
Dosage & Administration:
Pediatric Dose (1 to 11 years of age) | |||
Weight | Indication | Recommended Dose | Frequency |
| ≤ 30 kg | Short-Term Treatment of Symptomatic GERD & Short-Term Treatment of Erosive Esophagitis | 15 mg | Once daily for up to 12 weeks |
| > 30 kg | 30 mg | Once daily for up to 12 weeks | |
Pediatric Dose (12 to 17 years of age) (Short-Term Treatment of Symptomatic GERD) | ||
| Indication | Recommended Dose | Frequency |
| Nonerosive GERD | 15 mg | Once daily for up to 8 weeks |
| Erosive Esophagitis | 30 mg | Once daily for up to 8 weeks |
| Maintenance of Healing of Erosive Esophagitis | 15 mg | Once daily |
| Pathological Hyper-secretory Conditions Including Zollinger-Ellison syndrome | 60 mg | Once daily |
HOW SUPPLIED:
LANSORANGE-JR TABLET is available as Oral Disintegrating Tablets in 1 X 10 Packing
LANSORANGE TABLET is available as Tablets in 1 X 10 Packing
References:
- Paediatr Drugs. 2003;5(1):57-61
- Clinical Pharmacology of Lansoprazole in Infants and Children. J Pharmacol Clin Toxicol 10(1):1161.
- J Pediatr Gastroenterol Nutr. 2002;35 Suppl 4:S300-7.
